Anti Obesity Prescription Drugs

Anti Obesity Prescription Drugs Market Outlook

The global anti-obesity prescription drugs market is projected to reach a valuation of approximately USD 2.1 billion by 2035, growing at a CAGR of around 6.5% from 2025 to 2035. This growth is primarily driven by increasing obesity rates worldwide, which have been significantly rising due to changes in lifestyle, dietary habits, and a lack of physical activity. The growing prevalence of obesity-related diseases such as diabetes, heart disease, and hypertension is pushing both governments and healthcare organizations to focus on effective weight management solutions. Additionally, advancements in pharmaceutical research and an increasing acceptance of prescription medications for weight loss are contributing to the market's expansion. The ongoing development of innovative drug formulations and combination therapies also enhances treatment efficacy, appealing to a broader patient demographic.

Growth Factor of the Market

The anti-obesity prescription drugs market is experiencing robust growth due to multiple factors, including the rising incidence of obesity and associated co-morbidities. Increasing consumer awareness regarding weight management and health has led to a greater demand for effective pharmaceutical solutions. Moreover, the expansion of healthcare infrastructure and improved access to medical services are enabling a wider range of patients to seek treatment for obesity. The rising trend of preventive healthcare is encouraging more individuals to pursue weight loss medications to mitigate the risk of chronic diseases. Additionally, the continuous research and development efforts within the pharmaceutical industry are yielding new anti-obesity medications with better efficacy and safety profiles, thus attracting more patients to seek prescriptions for weight management.

Key Highlights of the Market

• The global anti-obesity prescription drugs market is projected to grow significantly over the next decade.
• A rise in obesity-related health concerns is a major driver of market growth.
• New drug formulations are being developed, enhancing the efficacy of weight management solutions.
• The increasing acceptance of pharmacotherapy for obesity management among healthcare professionals is notable.
• Telemedicine and online pharmacies are making access to these medications more convenient for patients.

By Product Type

Phentermine:

Phentermine is one of the most widely prescribed anti-obesity medications, functioning as a sympathomimetic amine that suppresses appetite. Its effectiveness is particularly noted in short-term weight management, and it has gained popularity due to its affordability and availability. Many patients prefer phentermine as it is generally well-tolerated and often results in noticeable weight loss when combined with lifestyle modifications. However, it's essential to monitor its use closely due to potential side effects and the risk of dependency. As healthcare providers increasingly recognize the importance of effective weight management, the demand for phentermine remains steady, contributing significantly to the overall market growth.

Orlistat:

Orlistat operates by inhibiting pancreatic lipase, thereby preventing the absorption of fats from the diet. It is unique as it provides a non-stimulant option for weight loss, appealing to patients who may be sensitive to stimulants or who have a history of adverse reactions to such medications. The efficacy of Orlistat is well-documented in clinical studies, and it is often recommended for long-term weight management. However, gastrointestinal side effects can be a concern for some patients, which may affect adherence to the treatment. As a result, Orlistat is a popular choice among those aiming for sustained weight loss, reinforcing its position in the anti-obesity prescription drugs market.

Lorcaserin:

Lorcaserin is a selective serotonin 2C receptor agonist that has gained recognition for its appetite-suppressing properties. The drug is designed to enhance satiety, making it easier for individuals to reduce calorie intake. Lorcaserin's focus on serotonin pathways differentiates it from other anti-obesity medications and offers a unique mechanism of action. While its efficacy is established, concerns regarding potential side effects, including mood-related changes, have affected its market penetration. Nevertheless, lorcaserin remains a viable option for weight management, particularly among patients who have not achieved desired results with other medications.

Bupropion/Naltrexone:

This combination therapy utilizes bupropion, an antidepressant that also aids in weight loss by influencing the brain's neurotransmitters, and naltrexone, which is used to manage opioid addiction. The dual action of these medications helps suppress appetite and reduce cravings, promoting better weight management outcomes. Its unique formulation appeals to patients who may benefit from a comprehensive approach addressing both psychological and physical aspects of obesity. The popularity of this combination is driven by its effectiveness and the growing emphasis on treating obesity as a multi-faceted health issue rather than just a physical concern.

Liraglutide:

Liraglutide is a GLP-1 receptor agonist originally developed for diabetes management but later approved for weight loss. Its mechanism involves enhancing insulin secretion and reducing appetite, thereby facilitating weight reduction. Liraglutide has garnered attention in the market due to its ability to deliver significant weight loss results, especially when utilized alongside dietary changes and physical activity. The medication’s association with various health benefits, including improved metabolic health markers, further boosts its attractiveness. Healthcare professionals increasingly recognize liraglutide as a viable option for overweight and obese patients, thus solidifying its position in the anti-obesity prescription drugs market.

By Application

Hospitals:

Hospitals play a critical role in the anti-obesity prescription drugs market as they are often the first point of contact for patients seeking weight management solutions. Healthcare professionals within hospital settings provide comprehensive evaluations and tailored treatment plans, utilizing a wide range of anti-obesity medications to address individual patient needs. Hospitals not only dispense medications but also offer support services such as nutritional counseling and physical therapy, promoting a multifaceted approach to obesity management. The presence of specialized weight management clinics within hospitals enhances the market's growth, as these facilities are equipped to facilitate ongoing patient education and support.

Clinics:

Clinics, including specialized weight management centers, contribute significantly to the prescription of anti-obesity drugs. Patients often seek treatment in these settings due to the personalized care and focused approach to weight loss. Clinics offer a combination of medication management, lifestyle counseling, and behavioral therapy, which can greatly enhance treatment outcomes. The one-on-one relationship between healthcare providers and patients fosters a supportive environment, encouraging adherence to prescribed regimens. As more individuals recognize the benefits of seeking professional help for weight management, clinics are expected to play an increasingly vital role in the anti-obesity prescription drugs market.

Retail Pharmacies:

Retail pharmacies serve as accessible points for patients to obtain anti-obesity medications, significantly influencing the overall market dynamics. Many patients prefer the convenience of picking up prescriptions at their local pharmacy, where they can also receive consultations from pharmacists about medication use and potential side effects. Retail pharmacies often partner with healthcare professionals to promote awareness about available weight management options, leading to increased patient engagement and medication adherence. The growing trend towards self-medication further boosts the demand for over-the-counter weight management options available at retail pharmacies, although prescription medications still dominate this segment.

Online Pharmacies:

Online pharmacies are becoming an increasingly popular avenue for obtaining anti-obesity prescription drugs due to the convenience of home delivery and greater accessibility. This trend has surged, particularly amid the COVID-19 pandemic, as individuals seek to limit in-person interactions. Online platforms provide a discreet and user-friendly experience for those seeking weight loss solutions, often incorporating telemedicine options for consultations with healthcare providers. However, while the growth of online pharmacies presents opportunities for market expansion, it also raises concerns regarding the authenticity of medications and the importance of ensuring patients receive legitimate prescriptions. This segment's growth is expected to continue as technology advances and patient preferences evolve towards digital solutions.

By Distribution Channel

Online Stores:

The rise of e-commerce has transformed the way consumers access anti-obesity medications, with online stores becoming a prominent distribution channel. This trend has been significantly expedited by the convenience and privacy that online shopping offers. Patients can order medications from the comfort of their homes, often avoiding the stigma associated with visiting brick-and-mortar pharmacies. Online stores provide detailed product information, user reviews, and easy price comparisons, empowering patients in their decision-making processes. Additionally, many online pharmacies are incorporating telehealth services, enabling patients to obtain consultations and prescriptions digitally, which further enhances accessibility and convenience.

Supermarkets/Hypermarkets:

Supermarkets and hypermarkets are increasingly stocking anti-obesity prescription drugs alongside health and wellness products. These retail giants leverage their expansive reach and established customer base to cater to health-conscious consumers looking for convenient access to weight management solutions. The availability of medications in these stores often comes with additional health products, such as dietary supplements and health foods, promoting a holistic approach to weight management. By providing these options, supermarkets and hypermarkets contribute to raising awareness about obesity and facilitate the integration of medications into broader lifestyle choices. While this trend may not dominate the market, it offers additional access points for consumers.

Specialty Stores:

Specialty stores dedicated to health and wellness products play a vital role in the distribution of anti-obesity prescription drugs. These stores often focus on providing a curated selection of medications and dietary aids aimed at weight loss, appealing to health-conscious consumers. Staffed by knowledgeable personnel, specialty stores can offer personalized advice and recommendations, enhancing the shopping experience for individuals seeking help with weight management. Furthermore, these stores may also provide additional resources, such as workshops and seminars on nutrition and weight loss strategies, thereby fostering community engagement and supporting consumers' health journeys.

Others:

This segment encompasses various distribution channels for anti-obesity prescription drugs that are not classified within the previously mentioned categories. It may include hospitals, clinics, and other healthcare facilities where medications are dispensed directly to patients. The importance of these channels lies in their ability to provide immediate access to medications following consultations and treatment plans. Moreover, some patients may obtain prescriptions through direct-to-consumer marketing initiatives, which may influence their purchasing decisions. The diversity of distribution channels contributes to the market's overall accessibility, ensuring that patients can find suitable options for their weight management needs.

By Ingredient Type

Sibutramine:

Sibutramine is a sympathomimetic drug that was once popular in the anti-obesity market due to its ability to suppress appetite effectively. It works by inhibiting the reuptake of neurotransmitters like serotonin and norepinephrine, leading to increased feelings of fullness. However, concerns regarding cardiovascular risks associated with its use have led to its withdrawal from several markets, impacting its overall presence in the anti-obesity prescription drugs sector. While sibutramine's effectiveness in aiding weight loss is well-documented, the safety profile and regulatory challenges have limited its market viability, shifting focus towards newer and safer alternatives.

Rimonabant:

Rimonabant is an endocannabinoid receptor antagonist that aimed to reduce appetite and promote weight loss. It is unique in its targeting of the endocannabinoid system, which plays a significant role in regulating appetite and energy balance. While clinical studies have demonstrated notable weight loss benefits associated with rimonabant, its association with psychiatric side effects, including depression and anxiety, led to its withdrawal from many markets. The experiences surrounding rimonabant have led to a cautious approach in the development of future anti-obesity drugs, emphasizing the need for safety in addition to efficacy.

Metformin:

Metformin is primarily known as an antidiabetic medication, but it has also been explored as an adjunct treatment for obesity, particularly in patients with insulin resistance. Its mechanism involves improving insulin sensitivity and reducing hepatic glucose production, which can facilitate weight loss in individuals with metabolic syndrome. While metformin is not officially approved solely as an anti-obesity drug, its off-label use in this context is becoming common, leading to increased prescriptions. The favorable safety profile and the added metabolic benefits of metformin contribute to its growing acceptance in managing weight among patients with concurrent metabolic disorders.

Topiramate:

Topiramate is an anticonvulsant that has shown potential for weight loss due to its appetite-suppressing effects. When combined with phentermine, it has been approved for obesity management under the brand name Qsymia. Topiramate's mechanism involves modulating neurotransmitter activity, which can help curb cravings and increase feelings of fullness. This combination therapy has gained traction among healthcare providers seeking effective weight loss solutions, particularly for patients who may not have succeeded with lifestyle changes alone. The dual-therapy approach of topiramate and phentermine exemplifies the trend toward multifaceted strategies for obesity treatment, which is becoming increasingly prominent in the market.

Phentermine/Topiramate:

The combination of phentermine and topiramate represents a significant advancement in obesity pharmacotherapy, as it harnesses the appetite-suppressing effects of both drugs to enhance weight loss outcomes. This combination therapy is designed for individuals who require a more aggressive approach to weight management, particularly those who have not achieved sufficient results with monotherapy. Clinical studies have demonstrated that this combination can lead to notable reductions in body weight and improved metabolic health. As healthcare providers increasingly adopt this dual-therapy approach, its presence in the anti-obesity prescription drugs market is expected to grow, catering to a patient population seeking effective solutions for weight management.

By Region

The North American region is experiencing significant growth in the anti-obesity prescription drugs market, driven by high obesity prevalence and rising healthcare costs associated with obesity-related diseases. In the United States, approximately 42.4% of adults are classified as obese, leading to a growing demand for effective weight management solutions. The market is expected to reach USD 1.2 billion by 2035, with a CAGR of 7.0% during the forecast period. The increasing acceptance of pharmacotherapy for weight loss and the presence of major pharmaceutical companies contribute to the robust growth in this region, making North America a key player in the global anti-obesity prescription drugs market.

In Europe, the anti-obesity prescription drugs market is also poised for growth, albeit at a slightly lower CAGR of 5.5% over the next decade. The European region faces similar challenges with rising obesity rates, which have prompted governments to implement public health initiatives promoting awareness about obesity management. Countries like Germany, France, and the United Kingdom are leading the way in terms of market share, with increasing investments in healthcare infrastructure and accessibility to weight management treatments. By 2035, the European market is anticipated to reach USD 600 million, reflecting a steady demand for anti-obesity medications amid growing concerns over public health.

Opportunities

The anti-obesity prescription drugs market presents numerous opportunities for growth, particularly with advancements in technology and the increasing acceptance of telehealth services. The integration of digital health platforms allows patients to access medications and consultations conveniently while enhancing their overall treatment experience. This trend is particularly appealing to a younger demographic that values accessibility and convenience in healthcare. As telehealth continues to grow, pharmaceutical companies have the chance to innovate their distribution strategies, creating partnerships with online pharmacies and telemedicine platforms to reach broader audiences. Additionally, the ongoing development of personalized medicine tailored to individual patient needs represents a significant opportunity for pharmaceutical companies to differentiate themselves in a competitive market.

Another noteworthy opportunity lies in the potential for developing combination therapies that address multiple aspects of obesity treatment, including appetite suppression, metabolic regulation, and behavioral modification. These multi-faceted approaches can improve patient outcomes and satisfaction, leading to higher adherence rates and better overall effectiveness. Furthermore, as consumer awareness regarding obesity and its associated risks continues to rise, there is a growing demand for comprehensive weight management programs that incorporate both pharmacotherapy and lifestyle modifications. Companies that position themselves as leaders in holistic obesity management strategies may find significant opportunities for growth and market expansion in the upcoming years.

Threats

Despite the positive outlook for the anti-obesity prescription drugs market, several threats could impede growth. One major challenge is the increasing scrutiny over the safety profiles of anti-obesity medications, particularly in light of past controversies surrounding certain drugs that have been withdrawn from the market due to adverse effects. Regulatory bodies are becoming more stringent in their evaluation processes, which may prolong the approval timelines for new drugs and limit the introduction of innovative formulations. Additionally, the public perception of anti-obesity medications can be influenced by negative media coverage, which may deter patients from seeking pharmacotherapy as a viable option for weight management. This skepticism could hinder market growth as patients may prefer lifestyle interventions over medications, impacting the overall demand for prescription drugs.

Moreover, the anti-obesity prescription drugs market faces competition from alternative weight loss solutions, including dietary supplements, herbal products, and non-pharmacological interventions. As consumers increasingly turn to these alternatives, the market for prescription medications may experience stagnation or slower growth. The lack of insurance coverage or reimbursement for anti-obesity medications can also pose a financial barrier for many patients, limiting their access to these treatments. Pharmaceutical companies must navigate these challenges by ensuring their products demonstrate clear advantages in efficacy and safety and by working with payers to improve reimbursement policies for obesity treatment.

Competitor Outlook

• Pfizer Inc.
• Roche Holding AG
• Orexigen Therapeutics, Inc.
• GlaxoSmithKline plc
• Allergan plc
• Amgen Inc.
• Novartis AG
• Sanofi S.A.
• Merck & Co., Inc.
• Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• AbbVie Inc.
• LifeSci Capital LLC
• VIVUS, Inc.
• Takeda Pharmaceutical Company Limited

The competitive landscape of the anti-obesity prescription drugs market is characterized by the presence of several leading pharmaceutical companies vying for market share. With ongoing research and development efforts, these companies are focused on delivering innovative weight management solutions that cater to the evolving needs of patients. The competition is intensified by the growing demand for effective anti-obesity medications, encouraging companies to invest substantially in their R&D pipelines. Partnerships and collaborations with healthcare providers and research institutions are common strategies adopted by these firms to enhance their product offerings and expand their market presence.

Major companies such as Pfizer Inc. have been at the forefront of developing anti-obesity medications, leveraging their extensive research capabilities to create effective solutions. Pfizer's product portfolio includes a range of medications that have received positive feedback for their efficacy and safety profiles. Similarly, GlaxoSmithKline plc is actively engaged in the research and development of innovative obesity treatments, focusing on combination therapies that target multiple pathways to address weight management effectively. Their commitment to addressing obesity as a multifaceted health issue positions them as key players in the market.

Another significant player, Novartis AG, has been investing in obesity pharmacotherapy and has pioneered several studies demonstrating the efficacy of its weight management solutions. The company’s focus on personalized medicine and patient-centric approaches enables it to tailor treatments based on individual needs, thus enhancing patient adherence and satisfaction. Similarly, Eli Lilly and Company is committed to advancing obesity treatments and has introduced groundbreaking therapies that significantly impact weight loss outcomes, gaining recognition within the healthcare community. The ongoing innovation and strategic positioning of these companies will shape the future of the anti-obesity prescription drugs market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 VIVUS, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Allergan plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 LifeSci Capital LLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eli Lilly and Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hoffmann-La Roche Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Orexigen Therapeutics, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Anti Obesity Prescription Drugs Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Retail Pharmacies
    • 6.1.4 Online Pharmacies
  • 6.2 Anti Obesity Prescription Drugs Market, By Product Type
    • 6.2.1 Phentermine
    • 6.2.2 Orlistat
    • 6.2.3 Lorcaserin
    • 6.2.4 Bupropion/Naltrexone
    • 6.2.5 Liraglutide
  • 6.3 Anti Obesity Prescription Drugs Market, By Ingredient Type
    • 6.3.1 Sibutramine
    • 6.3.2 Rimonabant
    • 6.3.3 Metformin
    • 6.3.4 Topiramate
    • 6.3.5 Phentermine/Topiramate
  • 6.4 Anti Obesity Prescription Drugs Market, By Distribution Channel
    • 6.4.1 Online Stores
    • 6.4.2 Supermarkets/Hypermarkets
    • 6.4.3 Specialty Stores
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Anti Obesity Prescription Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Anti Obesity Prescription Drugs market is categorized based on

By Product Type

• Phentermine
• Orlistat
• Lorcaserin
• Bupropion/Naltrexone
• Liraglutide

By Application

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Distribution Channel

• Online Stores
• Supermarkets/Hypermarkets
• Specialty Stores
• Others

By Ingredient Type

• Sibutramine
• Rimonabant
• Metformin
• Topiramate
• Phentermine/Topiramate

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Roche Holding AG
• Orexigen Therapeutics, Inc.
• GlaxoSmithKline plc
• Allergan plc
• Amgen Inc.
• Novartis AG
• Sanofi S.A.
• Merck & Co., Inc.
• Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• AbbVie Inc.
• LifeSci Capital LLC
• VIVUS, Inc.
• Takeda Pharmaceutical Company Limited